ivonescimab100 mgoneФл Ivonescimab is indicated for locally advanced or metastatic EGFR-mutated non-squamous non-small cell lung cancer (NSCLC) in patients who have experienced disease progression following treatment with EGFR tyrosine kinase inhibitors (TKIs)
Ivonescimab is indicated for locally advanced or metastatic EGFR-mutated non-squamous non-small cell lung cancer (NSCLC) in patients who have experienced disease progression following treatment with EGFR tyrosine kinase inhibitors (TKIs)
